η⁵-Pentamethylcyclopentadienylruthenium(II) Complexes containing η⁶-Co-ordinated Dipeptides with Aromatic Side Chains[†]

Andreas J. Gleichmann, Jens M. Wolff and William S. Sheldrick*

Lehrstuhl für Analytische Chemie, Ruhr-Universität Bochum, D-44780 Bochum, Germany

The η^{6} -co-ordinated amino acid complexes $[Ru(\eta^{5}-C_{g}Me_{g})(\eta^{6}-HaaOH)][CF_{3}SO_{3}]$ [HaaOH = L-HPheOH (phenylalanine) or L-HTrpOH (tryptophan)] were prepared by reaction of $[Ru(\eta^{5}-C_{g}Me_{g})(MeCN)_{3}][CF_{3}SO_{3}]$ with the relevant amino acid in tetrahydrofuran. Dipeptide complexes of the type $[\{Ru(\eta^{5}-C_{g}Me_{g})\}_{2}(\mu-\eta^{6}:\eta^{6}:pep)][CF_{3}SO_{3}]_{2}$ [pep = HPhe-PheOH, cyclo(-Phe-Phe-), HTrp-TrpOH, or cyclo(-Trp-Trp-)] may be obtained under analogous conditions. Ultraviolet irradiation of $[\{Ru(\eta^{5}-C_{g}Me_{g})\}_{2}(cyclo(-Phe-Phe-))][CF_{3}SO_{3}]_{2}$ leads to photochemical release of cyclo(-Phe-Phe-) in quantitative yield. The feasibility of peptide synthesis from individual amino acid complexes was demonstrated by the preparation of $[Ru(\eta^{5}-C_{g}Me_{g})\{\eta^{6}-cyclo(-Phe-Phe-)\}]CI from [Ru(\eta^{5}-C_{g}Me_{g})(\eta^{6}-$ L-HPhe-OMe)]CI by the carbodiimide method. A crystal structure analysis was carried out for $<math>[\{Ru(\eta^{5}-C_{g}Me_{g})\}_{2}(cyclo(-Phe-Phe-))][CF_{3}SO_{3}]_{2}$.

Interest in organometallic complexes of bioligands has increased rapidly in recent years, with the result that the term bioorganometallic chemistry has been coined to describe research in this area.^{1,2} Typical examples are $(\eta^6 - C_6 H_6)Ru^{II}$ or $(\eta^{5}-C_{5}Me_{5})M^{III}(M = Rh \text{ or } Co) \text{ complexes of } \alpha\text{-amino acids in}$ which the biological ligands are bi- or tri-dentate.³ Such organometallic complexes exhibit chiral centres both at the α -carbon atom in the ligand and at the metal and possess considerable potential for enantioselective synthesis of peptides.⁴ However, the number of characterised complexes containing direct metal-carbon bonds to ligands of biological interest is still somewhat limited, although the potential of this field has been emphasized in a recent review by Jaouen et al.¹ For instance Jaouen and co-workers⁵ have successfully developed the carbonylmetalloimmunoassay procedure based on the incorporation of organometallic fragments such as $Cr(CO)_3$ into steroid hormones. The same research team have also investigated the application of (n⁵-C₅Me₅)Ru^{II}-labelled molecules in the analysis and molecular recognition of active sites in hormone receptors.⁶ We have recently employed the same fragment for the first direct preparation of η^6 co-ordinated complexes of the a-amino acids phenylalanine (L-HPheOH), tyrosine (L-HTyrOH) and tryptophan (L-HTrpOH). Reaction of $[{Ru(\eta^5-C_5Me_5)Cl}_2(\mu-Cl)_2]$ with the respective amino acid (L-HaaOH) in MeOH-Na(OMe) gave $[Ru(\eta^5-C_5Me_5)(L-HaaOH)]CL^7$ The relationship of these sandwich complexes to the established radiopharmaceuticals ruthenocene and ruthenocenylalanine is apparent.⁸

These findings prompted us to investigate whether analogous $(\eta^{5}-C_{5}Me_{5})Ru^{II}$ complexes of dipeptides can be prepared either by direct reaction of the peptide with $[Ru(\eta^{5}-C_{5}Me_{5})(Me-CN)_{3}][CF_{3}SO_{3}]$ or through a peptide synthesis employing a cation of the type $[Ru(\eta^{5}-C_{5}Me_{5})(L-HaaOH)]^{+}$ as starting material. If successful, the second strategy should enable the synthesis of tailor-made $(\eta^{5}-C_{5}Me_{5})Ru^{II}$ -labelled peptides from chosen individual building blocks.

Experimental

Solvents were dried and distilled before use. Proton NMR spectra were recorded on a Bruker AM-400 spectrometer, IR spectra as KBr discs on a Perkin-Elmer 1760 spectrometer and FAB mass spectra on a VG Autospec instrument employing 3-nitrobenzyl alcohol as the matrix. Assignments of the resonances of the N (α_1,β_1)- and O (α_2,β_2)-terminal peptide protons were based on H-H correlation spectroscopy (COSY). Elemental analyses were performed on a Carlo Erba 1106 analyser. All reactions were carried out under argon by use of standard Schlenk techniques. The starting compound [Ru(η^5 -C₅Me₅)(MeCN)₃][CF₃SO₃] was prepared from RuCl₃•xH₂O (Heraeus) by the published procedure.⁹ The amino acids L-HPheOH and L-HTrpOH were obtained from Janssen, the dipeptides phenylalanylphenylalanine (HPhe-PheOH), cyclo-phenylalanylphenylalanine [cyclo(-Phe-Phe-)], tryptophyltryptophan [cyclo(-Trp-Trp-)] from Bachem. These compounds were used as received.

Syntheses.—[Ru(η^5 -C₅Me₅)(L-HPheOH)][CF₃SO₃] 1. The compound L-HPheOH (0.033 g, 0.2 mmol) was added to a solution of [Ru(η^5 -C₅Me₅)(MeCN)₃][CF₃SO₃] (0.102 g, 0.2 mmol) in tetrahydrofuran (thf) (6 cm³) and the solution stirred for 12 h at reflux. The yellow precipitate was centrifuged and the product 1 dissolved in a small volume of methanol. After filtration the solvent was removed in vacuum to afford complex 1 in 37% yield (0.041 g) (Found: C, 43.8; H, 4.8; N, 2.4. Calc. for C₂₀H₂₆F₃NO₅RuS: C, 43.6; H, 4.8; N, 2.5%). FAB mass spectrum: m/z 402 (100, $[M - CF_3SO_3]^+$), 356 (29, $[M - CF_3SO_3 - CO_2H]^+$) and 328 {24%, $[M - CF_3SO_3 - CH(NH_2)CO_2H]^+$ }. ¹H NMR (CD₃OD): δ 2.00 (s, 15 H, C₅Me₅), 2.82, 2.83 (2 d, 2 H, β -CH₂), 3.80 (t, 1 H, α -CH) and 5.85 (m, 5 H, η^6 -Ph). IR (KBr disc): $\tilde{\nu}$ /cm⁻¹ 3074m (NH) and 1636s (CO).

[{Ru(η^{5} -C₅Me₅)}₂(HPhe-PheOH)][CF₃SO₃]₂ **2**. A solution of [Ru(η^{5} -C₅Me₅)(MeCN)₃][CF₃SO₃] (0.102 g, 0.2 mmol) in thf (6 cm³) was stirred for 2 d at room temperature together with HPhe-PheOH (0.033 g, 0.1 mmol). The orange-yellow precipitate was centrifuged and the product **2** dissolved in a few cm³ of methanol. Remaining solid was filtered off and the solvent removed in vacuum to afford complex **2** in 37% yield (0.041 g) (Found: C, 43.5; H, 4.9; N, 2.4. Calc. for C₄₀H₅₀F₆N₂O₉Ru₂S₂·CH₃OH: C, 44.2; H, 4.9; N, 2.5%). FAB

[†] Supplementary data available: see Instructions for Authors, J. Chem. Soc., Dalton Trans., 1995, Issue 1, pp. xxv-xxx.

mass spectrum: $m/z \ 1085 \ (76, M^+), 935 \ (36, [M - CF_3SO_3]^+), 785 \ (24, [M - 2CF_3SO_3]^+) and 549 \ \{100\%, [M - 2CF_3-SO_3 - Ru(C_5Me_5)]^+\}.$ ¹H NMR (CD₃OD): $\delta \ 1.98 \ (2 \ s, 30 \ H, C_5Me_5), 2.70, 2.87 \ (2 \ dd, 2 \ H, \beta_2-CH_2), 2.87 \ (d, 2 \ H, \beta_1-CH_2), 4.18 \ (m, 1 \ H, \alpha_1-CH), 4.54 \ (m, 1 \ H, \alpha_2-CH) \ and 5.85 \ (m, 10 \ H, \eta^6-Ph).$ IR (KBr disc): $\tilde{\nu}/cm^{-1} \ 3380 \ (sh) \ (NH) \ and \ 1691s \ (CO).$

 $[{Ru(\eta^5-C_5Me_5)}_2{cyclo(-Phe-Phe-)}][CF_3SO_3]_2 3. The compound cyclo(-Phe-Phe-) (0.029 g, 0.1 mmol) was added to a$ solution of $[Ru(\eta^{5}-C_{5}Me_{5})(MeCN)_{3}][CF_{3}SO_{3}]$ (0.102 g, 0.2 mmol) in thf (6 cm³) and the solution stirred for 2 d at room temperature. The pale yellow precipitate was centrifuged and the product 3 dissolved in a small volume of methanol. After filtration the solvent was removed in vacuum to afford complex 3 in 40% yield (0.038 g) (Found: C, 44.1; H, 4.5; N, 2.7. Calc. for C₄₀H₄₈F₆N₂O₈Ru₂S₂·1.5CH₃OH: C, 44.8; H, 4.9; N, 2.5%). FAB mass spectrum: m/z 766 (9, $[M - 2CF_3SO_3]^+$), 531 $\{100, [M - 2CF_3SO_3 - Ru(C_5Me_5)]^+\}, 439\{20, [M - 2CF_3 SO_3 - Ru(C_5Me_5)(CH_2Ph)]^+$ and 328 {66%, [Ru(C_5Me_5)-(CH_2Ph)]^+}. ¹H NMR (CD_3OD): δ 1.95 (s, 30 H, C_5Me_5), 2.46, 2.82 (2 dd, 4 H, β-CH₂), 4.43 (t, 2 H, α-CH), 5.54, 5.77 and 5.83 (m, 10 H, η^6 -Ph). IR (KBr disc): $\tilde{\nu}/cm^{-1}$ 3270s (NH) and 1682vs (CO). Irradiation of a MeCN solution of 3 with a mercury lamp (254-380 nm) for 3 h led to precipitation of cyclo(-Phe-Phe-) in quantitative yield.

[Ru(η⁵-C₅Me₅)(L-HTrpOH)][CF₃SO₃] 4. A solution of [Ru(η⁵-C₅Me₅)(MeCN)₃][CF₃SO₃] (0.102 g, 0.2 mmol) in thf (6 cm³) was stirred for 5 h at reflux together with L-HTrpOH (0.041 g, 0.2 mmol). The solution was filtered and the product precipitated by addition of hexane. After centrifuging, the yellow product 4 was dissolved in a small volume of methanol, the solution filtered and the solvent removed in vacuum to afford complex 4 in 36% yield (0.042 g) (Found: C, 44.6; H, 4.7; N, 4.5. Calc. for C₂₂H₂₇F₃N₂O₅RuS: C, 44.8; H, 4.6; N, 4.8%). FAB mass spectrum: m/z 441 (100, $[M - CF_3SO_3]^+$) and 366 {50%, $[M - CF_3SO_3 - CH(NH_2)(CO_2H)]^+$ }. ¹H NMR (CD₃OD): δ 1.72 (2 s, 15 H, C₅Me₅), 3.20 (m, 2 H, β-CH₂), 3.95 (t, 1 H, α-CH), 5.60 (m, 2 H, indole H⁴, H⁵), 6.37, 6.39, 6.48, 6.56 (4 d, 2 H, indole H³, H⁶), 7.73 and 7.76 (2 s, 1 H, indole H⁹). IR (KBr disc): \tilde{v} /cm⁻¹ 3083m (NH) and 1636s (CO).

 $[{Ru(\eta^5-C_5Me_5)}_2(HTrp-TrpOH)][CF_3SO_3]_2$ 5. The compound HTrp-TrpOH (0.043 g, 0.1 mmol) was added to a solution of $[Ru(\eta^5-C_5Me_5)(MeCN)_3][CF_3SO_3]$ (0.102 g, 0.2 mmol) in thf (6 cm³) and the solution stirred for 3 d at reflux. After filtering the product was precipitated from the filtrate by addition of hexane. The solid was centrifuged and the orangeyellow product 5 dissolved in a few cm³ of methanol. After filtration of remaining solid the solvent was removed in vacuum to afford complex 5 in 46% yield (0.055 g) (Found: C, 45.0; H, 4.6; N, 4.6. Calc. for C₄₄H₅₂F₆N₄O₉Ru₂S₂·CH₃OH: C, 45.3; H, 4.7; N, 4.7%). FAB mass spectrum: m/z 1145 (6, M⁺), 994 $(23, [M - CF_3SO_3]^+), 845 (13, [M - 2CF_3SO_3]^+), 609 \{17,$ $[M - 2CF_3SO_3 - Ru(C_5Me_5)]^+$ and 366 {100%, $[M - 2CF_3SO_3 - Ru(C_5Me_5)(C_9H_8N)]^+$ }. ¹H NMR (CD₃OD): δ 1.63, 1.64, 1.65, 1.66 (4 s, 30 H, C₅Me₅), 2.24, 2.48 (2 dd, 2 H, β_2 -CH₂), 2.74 (2 dd, 2 H, β_1 -CH₂), 4.17 (m, 1 H, α_2 -CH), 4.32 (m, 1 H, α_1 -CH), 5.46 (m, 4 H, indole H⁴, H⁵), 6.30 (m, 4 H, indole H³, H⁶), 7.34 and 7.44 (2 s, 1 H, indole H⁹). IR (KBr disc): v/cm⁻¹ 3397m (NH) and 1679s (CO).

 $[\{Ru(\eta^5-C_5Me_5)\}_2 \{cyclo(-Trp-Trp-)\}] [[CF_3SO_3]_2 6. A solution of [Ru(\eta^5-C_5Me_5)(MeCN)_3] [[CF_3SO_3] (0.102 g, 0.2 mmol) in thf (6 cm³) was stirred for 3 h at reflux together with cyclo(-Trp-Trp-) (0.037 g, 0.1 mmol). The dark green solution was filtered and the product precipitated by addition of hexane. The dark green product was subsequently dissolved in a small quantity of methanol, the solution filtered and the solvent removed in vacuum to afford complex 6 in 33% yield (0.038 g) (Found: C, 45.6; H, 4.6; N, 4.3. Calc. for C₄₄H₅₀F₆N₄O₈Ru₂S₂· CH₃OH: C, 45.9; H, 4.6; N, 4.8%). FAB mass spectrum: <math>m/z$ 845 (39, $[M - 2CF_3SO_3]^+$), 609 {45, $[M - 2CF_3SO_3 - Ru(C_5Me_5)]^+$ } and 366 {100%, $[M - 2CF_3SO_3 - Ru(C_5Me_5)]^+$ }

Ru(C₅Me₅)(C₉H₈N)]⁺}. ¹H NMR (CD₃OD): δ 1.65 (m, 30 H, C₅Me₅), 2.74 (m, 4 H, β-CH₂), 4.26 (m, 2 H, α-CH), 5.44 (m, 4 H, indole H⁴, H⁵), 6.26 (m, 4 H, indole H³, H⁶), 7.35 and 7.46 (2 s, 2 H, indole H⁹). IR (KBr disc): $\tilde{\nu}$ /cm⁻¹ 3270s (NH) and 1679vs (CO).

 $[Ru(\eta^5-C_5Me_5)(Bu'OCO-Phe-Phe-OMe)]Cl 7$. The compound phenylalanine methyl ester (HPhe-OMe) (0.057 g, 0.32 mmol) was added to a solution of $[{Ru(\eta^5-C_5Me_5)Cl}_2 (\mu$ -Cl)₂] (0.100 g, 0.16 mmol) in methanol (50 cm³) and the solution stirred for 3 h at 80 °C. After removal of the solvent, the resulting yellow solid was dissolved in methanol (3 cm^3) and the solution filtered. Addition of CH₂Cl₂ (3 cm³) led to precipitation of $[Ru(\eta^5-C_5Me_5)(HPhe-OMe)]Cl$, which was filtered off and dried (yield 0.113 g, 94%). FAB mass spectrum: m/z 416 (78%, $[M - Cl]^+$). ¹H NMR (CD₃OD): δ 2.01 (s, 15 H, C₅Me₅) and 6.04 (m, 5 H, η^6 -Ph). The peptide complex 7 was prepared by the carbodiimide method.¹⁰ The complex $[Ru(\eta^5-C_5Me_5)(HPhe-OMe)]Cl(0.076 g, 0.2 mmol)$ was added to a solution of the N-protected amino acid Bu'OCO-PheH (0.036 g, 0.2 mmol) in CH_2Cl_2 (5 cm³). After addition of triethylamine (0.2 mmol) and the coupling reagent N-(3dimethylaminopropyl)-N'-ethylcarbodiimide the suspension was stirred for 12 h at -50 °C. The mixture was then treated with water (5 cm³), 1 mol dm⁻³ citric acid (5 cm³) and Na₂CO₃ (5 cm^3) to afford complex 7 as a light brown solid after solvent removal (yield 0.128 g, 92%) (Found: C, 58.0; H, 6.4; N, 3.8. Calc. for $C_{34}H_{45}ClN_2O_5Ru$: C, 58.5; H, 6.5; N, 4.0%). FAB mass spectrum: m/z 663 (100%, $[M - Cl]^+$). ¹H NMR (CD₃OD): δ 1.34 (m, 9 H, Bu^t), 2.02 (s, 15 H, C₅Me₅), 2.98 (m, 4 H, β -CH₂), 3.75 (m, 3 H, CH₃), 4.30 (m, 1 H, α -CH), 4.70 (m, 1 H, α -CH), 5.83 (m, 5 H, η^6 -Ph) and 7.25 (m, 5 H, Ph).

[Ru(η⁵-C₅Me₅){cyclo(-Phe-Phe-)}]Cl 8. The Bu'OCO protecting group in complex 7 (0.140 g, 0.2 mmol) was removed in 98% acetic acid (10 cm³) with the solvent being removed in vacuum after 2 h. The cyclisation to 8 was performed in a mixture of *sec*-butyl alcohol (10 cm³) and toluene (2 cm³) according to Nitecki and Westley.¹¹ After stirring for 2 h at 80 °C the solvent was removed to afford complex 8 in 90% yield (0.102 g) (Found: C, 58.8; H, 5.8; N, 4.5. Calc. for C₂₈H₃₃ClN₂O₂Ru: C, 59.4; H, 5.9; N, 4.9%). FAB mass spectrum: *m*/*z* 529 (100%, [*M* - Cl]⁺). ¹H NMR (CD₃OD): δ 1.95 (s, 15 H, C₅Me₅), 2.95 (m, 4 H, β -CH₂), 4.10, 4.31 (2 m, 2 H, α -CH), 5.73 (m, 5 H, η⁶-Ph) and 7.29 (m, 5 H, Ph).

X-Ray Crystallography.—Suitable crystals of $[{Ru(\eta^5-C_5Me_5)}_2(cyclo(-Phe-Phe-)}][CF_3SO_3]_2\cdot1.5MeOH were obtained by layering a solution of complex 3 in CH_2Cl_2-MeOH (80:20) with hexane.$

Crystal data. $C_{40}H_{48}F_6N_2O_8Ru_2S_2\cdot 1.5CH_3OH$, M = 1113.1, orthorhombic, space group $P2_12_12_1$, a = 11.896(5), b = 16.996(6), c = 22.694(5) Å, U = 4588(3) Å³ (by least-squares refinement on diffractometer angles for 25 automatically centred reflections, $\lambda = 0.71073$ Å), T = 173 K, Z = 4, $D_c = 1.60$ g cm⁻³, F(000) = 2244. Pale yellow plates. Crystal dimensions: $0.53 \times 0.36 \times 0.31$ mm, μ (Mo-K α) = 8.29 cm⁻¹.

Data collection and processing. Siemens P4 diffractometer, ω mode with scan speed 2.1–22.6° min⁻¹, graphite-monochromated Mo-K_{\alpha} radiation; 3877 unique reflections measured ($4.0 \le 2\theta \le 45^\circ$, +h,k,l), absorption correction for the lowtemperature data with DIFABS,¹² no significant alterations observed in the control intensities monitored every 100 reflections.

Structure analysis and refinement. Direct methods (Ru atoms) followed by standard heavy-atom procedures. Full-matrix least squares on $|F^2|$ with hydrogen atoms for the phenyl, piperazine and one of the C₅Me₅ rings [C(51)–C(55)] at calculated positions. The second C₅Me₅ ligand [C(51')–C(55')] is disordered with site occupation factors (s.o.f.) of 0.41(2) and 0.59(2). The C₅Me₅ ring systems were refined as rigid groups. Disorder was also observed for the second CF₃SO₃⁻ anion

I able I				complex 5 with estin				Z
	Atom	x	у	Ζ	Atom	x	у	
	Ru	6 255(1)	5 068(1)	268(1)	C(36')	8 199(11)	8 646(6)	2 290(5)
	Ru'	8 880(1)	7 504(1)	2 614(1)	C(1)	5 003(12)	7 978(7)	459(5)
	C(31)	6 073(11)	6 362(6)	308(4)	O(1)	4 004(7)	7 804(5)	359(4)
	C(32)	5 187(12)	5 998(8)	611(5)	C(2)	5 858(10)	7 786(6)	1(5)
	C(33)	5 382(14)	5 448(8)	1 080(5)	N(2)	7 013(9)	8 022(6)	158(4)
	C(34)	6 473(12)	5 243(8)	1 230(5)	C(3)	5 853(10)	6 912(6)	-187(4)
	C(35)	7 366(12)	5 604(10)	934(5)	C(1')	7 292(10)	8 443(6)	629(5)
	C(36)	7 197(10)	6 154(7)	473(5)	O(1')	8 244(7)	8 732(5)	682(4)
	C(41)	5 831(5)	3 851(3)	91(3)	C(2')	6 488(10)	8 498(7)	1 127(5)
	C(42)	7 001(5)	3 963(3)	-12(2)	N(2')	5 343(8)	8 340(5)	945(4)
	C(43)	7 123(5)	4 520(3)	-477(2)	C(3')	6 827(10)	7 918(7)	1 625(5)
	C(44)	6 028(5)	4 751(3)	-662(2)	S(100)	607(3)	5 316(2)	897(2)
	C(45)	5 229(5)	4 338(3)	-311(2)	O(110)	112(9)	6 027(6)	1 109(5)
	C(51)	5 316(7)	3 309(4)	546(4)	O(120)	759(10)	5 303(6)	266(5)
	C(52)	7 949(7)	3 561(5)	316(4)	O(130)	137(9)	4 608(6)	1 141(6)
	C(53)	8 224(6)	4 813(5)	-730(4)	C(100)	2 029(14)	5 376(11)	1 178(7)
	C(54)	5 760(7)	5 335(5)	-1 146(3)	F(110)	2 522(8)	6 028(7)	1 014(5)
	C(55)	3 963(7)	4 405(5)	- 358(4)	F(120)	2 042(9)	5 336(7)	1 755(4)
	C(41')	8 407(10)	7 354(7)	3 554(5)	F(130)	2 640(10)	4 787(7)	998(6)
	C(42')	9 549(10)	7 118(7)	3 476(5)	S(200)	3 781(4)	8 517(3)	2 473(2)
	C(43')	9 572(10)	6 493(7)	3 056(5)	O(211)	2 884(13)	8 887(13)	2 807(6)
	C(44')	8 444(11)	6 342(7)	2 874(6)	O(221)	4 761(12)	8 273(14)	2 809(7)
	C(45')	7 723(10)	6 874(8)	3 182(6)	O(231)	4 010(17)	8 868(14)	1 904(6)
	C(51')	7 991(15)	8 000(11)	3 961(8)	O(212)	2 855(12)	8 571(19)	2 887(7)
	C(52')	10 562(14)	7 471(11)	3 786(8)	O(222)	4 891(10)	8 677(14)	2 703(7)
	C(53')	10 613(14)	6 064(11)	2 841(9)	O(232)	3 552(15)	8 772(13)	1 880(5)
	C(54')	8 074(17)	5 725(11)	2 431(8)	C(201)	3 589(16)	7 474(13)	2 414(8)
	C(55')	6 454(15)	6 921(12)	3 124(9)	F(211)	3 772(17)	7 235(12)	2 970(7)
	C(41″)	8 005(9)	7 144(6)	3 419(4)	F(221)	4 301(17)	7 080(16)	2 066(9)
	C(42")	9 195(9)	7 123(6)	3 500(4)	F(231)	2 549(15)	7 239(14)	2 270(8)
	C(43″)	9 646(8)	6 545(5)	3 109(4)	C(202)	3 540(18)	7 476(13)	2 322(8)
	C(44")	8 735(8)	6 208(5)	2 787(4)	F(212)	3 420(17)	6 901(12)	2 739(8)
	C(45")	7 720(8)	6 578(5)	2 979(4)	F(222)	4 337(18)	7 177(17)	1 953(10)
	C(51")	7 185(13)	7 673(9)	3 745(6)	F(232)	2 576(17)	7 417(14)	2 000(9)
	C(52")	9 864(13)	7 628(9)	3 927(6)	C(301)	6 150(44)	1 014(29)	923(13)
	C(53")	10 879(11)	6 328(9)	3 047(7)	O(301)	6 071(21)	1 274(12)	292(11)
	C(54")	8 827(12)	5 568(7)	2 322(6)	C(302)	6 182(50)	525(26)	879(20)
	C(55")	6 545(11)	6 400(9)	2 753(7)	O(302)	6 135(34)	1 380(16)	712(18)
	C(31')	7 973(11)	8 065(7)	1 855(5)	C(303)	4 553(87)	5 214(43)	2 542(41)
	C(32')	8 898(10)	7 624(6)	1 646(4)	O(303)	4 047(51)	4 512(31)	2 240(23)
	C(33')	9 978(14)	7 762(8)	1 850(5)	O(304)	4 067(52)	5 211(36)	2752(24)
	C(34')	10 195(13)	8 338(7)	2 294(5)	C(304)	3 554(38)	5 484(24)	3 321(18)
	C(35')	9 250(11)	8 767(7)	2 521(5)				

Table 1 Fractional atomic coordinates (× 10⁴) for complex 3 with estimated standard deviations (e.s.d.s) in parentheses

Table 2 Selected bond lengths (Å)


Ru–C(31)	2.211(9)	Ru'-C (31')	2.245(11)
RuC(32)	2.172(13)	Ru'-C(32')	2.206(9)
Ru–C(33)	2.210(13)	Ru'C(33')	2.215(13)
Ru-C(34)	2.218(11)	Ru'-C(34')	2.230(12)
Ru-C(35)	2.204(13)	Ru'-C(35')	2.201(12)
Ru-C(36)	2.209(11)	Ru'-C(36')	2.228(11)
Ru-C(41)	2.167(5)	Ru'-C(41')	2.222(11)
RuC(42)	2.172(5)	Ru'- C(42')	2.212(11)
Ru-C(43)	2.189(5)	Ru'-C(43')	2.153(12)
Ru-C(44)	2.195(5)	Ru'-C(44')	2.125(13)
Ru-C(45)	2.181(5)	Ru'-C(45')	2.168(13)
C(31)-C(3)	1.49(1)	C(31')-C(3')	1.48(2)
C(3) - C(2)	1.54(2)	C(3') - C(2')	1.55(2)
C(2) - C(1)	1.49(2)	C(2') - C(1')	1.48(2)
C(1) - O(1)	1.25(2)	C(1')-O(1')	1.24(1)
C(2) - N(2)	1.48(2)	C(2') - N(2')	1.45(2)
C(1)-N(2')	1.33(2)	C(1')-N(2)	1.33(1)

[S(200), C(200), s.o.f. 0.5 for the O and F positions] and for the methanol molecules which display four different sites (s.o.f. 0.56, 0.40, 0.39 and 0.15). Anisotropic thermal parameters were introduced for those non-hydrogen atoms which were not disordered. Weighting scheme: $w = 1/[\sigma^2(F_o^2) + (0.0807P)^2 + 5.57P]$ with $P = [\max (F_o^2, 0) + 2F_c^2]/3$. Final reliability indices: R = 0.049 [2974 reflections with $I > 2\sigma(I)$] and 0.068 for all 3877 reflections, $wR_2 = 0.122$ [$I > 2\sigma(I)$] and 0.139 (all data). Maximum, minimum residual electron density: 0.60, -0.55 e Å⁻³. Structure solution and refinement with SHELXS^{13a} and SHELXL.^{13b} Fractional atomic coordinates are listed in Table 1, selected bond lengths in Table 2.

Additional material available from the Cambridge Crystallographic Data Centre comprises thermal parameters and remaining bond lengths and angles.

Results and Discussion

Reaction of $[Ru(\eta^{5}-C_{5}Me_{5})(MeCN)_{3}][CF_{3}SO_{3}]$ with the phenylalanine derivatives L-HPheOH, HPhe-PheOH and cyclo(-Phe-Phe-) in thf leads to the formation of the η^{6} -coordinated complexes 1–3 in satisfactory yields. The ¹H NMR spectra (400 MHz, CD₃OD) of these sandwich complexes all exhibit a characteristic upfield shift for the phenyl protons from δ 7.2–7.4 in the free amino acid or peptide to δ 5.54–5.85 in the η^{6} -co-ordinated ligand, as has been observed for other η^{6} -coordinated arenes.^{6,7} At the beginning of this work it was not certain from previous studies whether the potential N and O donor atoms in L-HPheOH or the dipeptides HPhe-PheOH and cyclo(-Phe-Phe-) would inhibit η^{6} co-ordination of the (η^{5} - $C_{5}Me_{5}$)Ru^{II} moiety to the phenyl ring. For instance, effectively quantitative formation of the $\kappa^{2}N$,O-co-ordinated chelate



complex $[Ru(\eta^5-C_5Me_5)Cl(L-HPheO)]^-$ is observed in the reaction of $[{Ru(\eta^5-C_5Me_5)Cl}_2(\mu-Cl)_2]$ with L-HPheOH in methanol at temperatures below 0 °C. In contrast, the entropically favoured sandwich complex $[Ru(\eta^5-C_5Me_5)(\eta^6-L-HPheOH)]^+$ may be prepared in 88% yield by the same reaction at reflux. However, the reaction mixture still contains about 10% of the $\kappa^2 N$, O-co-ordinated half-sandwich complex. Use of $[Ru(\eta^5-C_5Me_5)(MeCN)_3][CF_3SO_3]$ as a starting material leads only to the precipitation of the η^6 -co-ordinated complexes 1–3 during the course of the reaction. Whereas more forcing conditions are required for 1 (12 h reflux), the reaction with the dipeptides may be performed at room temperature (2 d). This kinetic aspect may reflect the fact that the competitive formation a $\kappa^2 N$, O-co-ordinated five-membered chelate ring as for L-HPheOH will be energetically much less favourable for HPhe-PheOH and is not possible for cyclo(-Phe-Phe-).

Complex 1 displays a strong v(CO) absorption band at 1636 cm⁻¹, a value typical for deprotonated carboxylate groups, which suggests that the η^6 -co-ordinated amino acid adopts a zwitterionic structure in this complex. The C_5Me_5 proton resonances in 1-3 are observed at respectively δ 2.00 (s), 1.98 (2 s) and 1.95 (s). As may be seen in Fig. 1, the ruthenium(II) sandwich systems in the cation $[{Ru(\eta^5-C_5Me_5)}_2{cyclo(-Phe-$ Phe-) $]^{2+}$ 3 adopt orientations which are approximately perpendicular to one another. This conformation, which leads to a minimisation of intramolecular interaction between the constituent π systems, may also be gauged from the torsion angles of -59.5 and 58.8° for C(1)–C(2)–C(3)–C(31) and C(1')-C(2')-C(3')-C(31') respectively. The central six-membered ring system exhibits a significant deviation from planarity with the atoms C(1') and C(2') displaced respectively 0.12 and -0.14 Å from the best least-squares plane through the remaining atoms. Relevant torsion angles are 18.6° for C(2)-N(2)-






Fig. 1 Molecular structure of the cation $[{Ru(\eta^{5}-C_{5}Me_{5})}_{2}$ {cyclo-(-Phe-Phe-)}]²⁺ of complex 3

C(1')-C(2'), -22.4° for N(2)-C(1')-C(2')-N(2') and 18.2° for C(1')-C(2')-N(2')-C(1). A singlet is observed for the C_5Me_5 methyl protons in CD₃OD solution, indicating the equivalence of the (η^5 -C₅Me₅)Ru^{II} sandwiches of 3 on the NMR time-scale. This is also the case for the α -protons which exhibit a triplet at δ 4.43 but not for the β -protons for which doublets of doublets are observed at δ 2.46 (H^β) and 2.82 (H^β) [J(H^βH^β)] = 14.0, J(H^αH^β) = 3.7, J(H^αH^β) = 4.9 Hz]. A similar phenomenon was recorded for the O-terminal β_2 protons in [{Ru(η^5 -C₅Me₅)}₂(HPhe-PheOH)]²⁺ 2, which display a J(H^β₂H^{β₂}) value of 8.4 Hz [J(H^{α₂H^{β₂})] = 5.1 Hz]. In contrast, the isochronous N-terminal β_1 protons in 2 yield only a single doublet with J(H^{α₁}H^{β₁}) = 4.6 Hz.}

The analogous reaction of $[Ru(\eta^5-C_5Me_5)(MeCN)_3]$ -[CF₃SO₃] with the tryptophan derivatives L-HTrpOH, HTrp-TrpOH and cyclo(-Trp-Trp-) in thf affords the n⁶-coordinated sandwich complexes 4-6. As these products are soluble in thf, precipitation must be induced by addition of hexane. η^{6} -Co-ordination of the indole six-membered ring is confirmed by the characteristic upfield shifts of the NMR proton resonances H³-H⁶ to δ 5.44-5.60 (H⁴, H⁵) and 6.26-6.56 (H³, H⁶). In contrast, the aromatic proton H⁹ of the uncoordinated five-membered ring experiences only a marginal shift (δ 7.34–7.76). Similar chemical shifts have recently been reported by Trudell and co-workers¹⁴ for the indole protons in the analogous n⁶-co-ordinated tryptamine (indole-3-ethanamine)derivative[Ru(n⁵-C₅Me₅)(n⁶-trpa)][CF₃SO₃].Interestingly, these authors were only able to synthesise this sandwich complex by use of the N-protected η^6 -co-ordinated derivatives $[Ru(\eta^5-C_5Me_5)(\eta^6-Bu^4OCO-trpa)][CF_3SO_3]$ and $[Ru(\eta^5-C_5Me_5)(\eta^6-Bu^4OCO-trpa)][CF_3SO_3]$ C_5Me_5)(η^6 -PhCH₂OCO-trpa)][CF₃SO₃]. In contrast to the present study on tryptophan derivatives, direct reaction of $[Ru(\eta^{5}-C_{5}Me_{5})(MeCN)_{3}][CF_{3}SO_{3}]$ with tryptamine was observed to lead only to the formation of metastable $[Ru(\eta^5 -$ C₅Me₅)(MeCN)₂(trpa)][CF₃SO₃], in which the indole derivative displays a $\kappa^1 N(amino)$ co-ordination. Attempts to convert this σ complex into the entropically favoured sandwich complex $[Ru(\eta^5-C_5Me_5)(\eta^6-trpa)][CF_3SO_3]$ were unsuccessful.¹⁴

Of particular interest is the observation of two singlets at δ 1.72 (approximate ratio 50:50) for the C₅Me₅ methyl protons in [Ru(η^5 -C₅Me₅)(L-HTrpOH)][CF₃SO₃] **4**, which are indicative of the presence of diastereomers caused by facial chirality at the ruthenium atom. The use of both sides of the sixmembered indole ring for η^6 co-ordination is also evidenced by the observation of four doublets for the protons H³ and H⁶ and two singlets for H⁹. Singlets (δ 1.63–1.66) for each of the four possible diastereomers of [{Ru(η^5 -C₅Me₅)}₂(HTrp-TrpOH)]²⁺ **5** were recorded in the ¹H NMR spectrum of this dipeptide complex. A broad signal at δ 1.65 also indicates the presence of diastereomers in a solution of [{Ru(η^5 -C₅Me₅)}₂{cyclo(-Trp-Trp-)}]²⁺ **6**. Surprisingly Trudell and coworkers¹⁴ reported only the presence of singlets for the C₅Me₅ methyl protons in the ¹H NMR spectra of their analogous






5

6

tryptamine derivatives. As for the phenylalanine complex 1, the IR spectrum of $[Ru(\eta^5C_5Me_5)(L-HTrpOH)][CF_3SO_3]$ 4 exhibits a strong v(CO) absorption at 1636 cm⁻¹, indicating that the η^6 -co-ordinated amino acid HTrpOH is also present as a zwitterion.

The suitability of η^6 -co-ordinated building blocks of the type $[Ru(\eta^{5}-C_{5}Me_{5})(HaaOH)]^{+}$ for the synthesis of $(\eta^{5}-C_{5}Me_{5})Ru^{II}$ -labelled peptides was investigated using the carbodiimide method¹⁰ for the simple example $[Ru(\eta^{5}-C_{5}Me_{5})Ru^{II}]$ C_5Me_5 (cyclo(-Phe-Phe-)]⁺ 8. The required starting material $[Ru(\eta^5 - C_5 Me_5)(L-HPhe-OMe)]Cl$ was obtained by reaction of $[{Ru(\eta^5-C_5Me_5)Cl}_2(\mu-Cl)_2]$ with phenylalanine methyl ester (L-HPhe-OMe) in methanol at reflux. This complex was then added to a CH2Cl2 solution of the N-protected amino acid Bu'OCO-PheOH in the presence of base (NEt₃) and the coupling reagent N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide to yield the peptide derivative 7. After removal of the Nprotection group in 98% acetic acid, cyclisation to the η^6 -coordinated ligand cyclo(-Phe-Phe-) was performed in sec-butyl alcohol-toluene (4:1) at reflux. The product 8 exhibits respective multiplets at δ 5.73 and 7.29 for the co-ordinated and unco-ordinated phenyl groups. Attempts to prepare the cation $[Ru(\eta^{5}-C_{5}Me_{5}){cyclo(-Phe-Phe-)}]^{+}$ by direct reaction of $[Ru(\eta^{5}-C_{5}Me_{5})(MeCN)_{3}][CF_{3}SO_{3}]$ with cyclo(-Phe-Phe-) in a 1:1 molar ratio led to preferred formation of the 2:1 complex 3.

An analogous $(\eta^5 - C_5 Me_5)Ru^{II}$ labelling of biologically relevant peptides could open new analytical perspectives for the investigation of receptor sites. In this respect it is interesting that η^6 -co-ordinated arenes in sandwich complexes of the type $[Ru(\eta^5 - C_5 Me_5)(\eta^6 - arene)]^+$ may be photochemically released.¹⁵ We have studied the feasibility of this procedure for peptide complexes by irradiating a MeCN solution of $[{Ru(\eta^5 - C_5 Me_5)}_2(cyclo(-Phe-Phe-))][CF_3SO_3]_2$ 3 with a mercury



lamp (254–380 nm) for 3 h, which leads to release of cyclo(-Phe-Phe-) as a white precipitate in quantitative yield.

Koefod and Mann¹⁶ have demonstrated that kinetically controlled η^6 co-ordination of the $(\eta^5-C_5Me_5)Ru^{II}$ moiety leads to a preference for partially localised arene π systems (*e.g.* indole) over arene π systems which are highly delocalised (*e.g.* phenyl). This kinetically derived chemospecificity was also confirmed by Trudell and co-workers¹⁴ for N-

benzyloxycarbonyl-N-methoxytryptamine which affords the η^6 -co-ordinated indole derivative [Ru(η^5 -C₅Me₅)(MeO-Ph-CH₂OCO-trpa)][CF₃SO₃] in 92% yield. The $(\eta^{5}-C_{5}Me_{5})Ru^{II}$ fragment obviously differentiates between two electron-rich arenes, preferring the indole six-membered ring over the highly delocalised phenyl ring of the PhCH₂OCO protection group. This finding prompted us to study the reactions of [Ru- $(\eta^{5}-C_{5}Me_{5})(MeCN)_{3}$ [CF₃SO₃] and [{Ru($\eta^{5}-C_{5}Me_{5}$)Cl $_{2}(\mu$ -Cl)₂] with mixed dipeptides such as HPhe-TrpOH and HTrp-PheOH. Our preliminary results have demonstrated that only the indole-co-ordinated 1:1 complexes [Ru(η^5 -C₅Me₅)(HPhe-TrpOH)]Cl and [Ru(n⁵-C₅Me₅)(HTrp-PheOH)]Cl may be isolated by size-exclusion chromatography (Sephadex LH-20) from the product mixtures which result from the reaction of $[\{Ru(\eta^5 \mathchar`C_5 Me_5) Cl\}_2(\mu \mathchar`Cl)_2]$ with the relevant dipeptide in a 1:1 molar ratio.

Our present results indicate the potential of $(\eta^5-C_5Me_5)Ru^{II}$ labelling of peptides with aromatic side chains by demonstrating that the reaction of $[Ru(\eta^5-C_5Me_5)(MeCN)_3][CF_3SO_3]$ with chosen dipeptides leads to the formation of entropically favoured sandwich complexes rather than the alternative $\kappa^1 N$ - or $\kappa^2 N$, O-co-ordinated derivatives. Such η^6 -co-ordinated bioligands may be photochemically released at a later stage. Preliminary results suggest that a chemospecific co-ordination of indole six-membered rings may be expected.

References

- 1 G. Jaouen, A. Vessières and I. S. Butler, Acc. Chem. Res., 1993, 26, 361.
- 2 D. P. Smith, E. Baralt, B. Morales, M. M. Olmstead, M. F. Maestre and R. H. Fish, J. Am. Chem. Soc., 1992, 114, 10647.
- 3 W. S. Sheldrick and S. Heeb, J. Organomet. Chem., 1989, 377, 357; D. Carmona, A. Mendoza, F. J. Lahoz, L. A. Oro, M. P. Lamata and E. San Jose, J. Organomet. Chem., 1990, 396, C17; R. Krämer,

K. Polborn, H. Wanjek, I. Zahn and W. Beck, *Chem. Ber.*, 1990, 123, 767;
R. Krämer, K. Polborn and W. Beck, *Chem. Ber.*, 1991, 124, 2429;
W. S. Sheldrick, E. Hauck and S. Korn, *J. Organomet. Chem.*, 1994, 467, 283.

- 4 W. Beck and R. Krämer, Angew. Chem., Int. Ed. Engl., 1991, 30, 1467.
- 5 A. Vessières, M. Salmain, V. Philomin and G. Jaouen, *Immunoanal. Biol. Spec.*, 1992, **31**, 9; M. Salmain, A. Vessières, P. Brossier, I. S. Butler and G. Jaouen, J. *Immunol. Methods*, 1992, **148**, 65.
- 6 D. Vichard, M. Gruselle, H. El Amouri and G. Jaouen, J. Chem. Soc., Chem. Commun., 1991, 46; D. Vichard, M. Gruselle, H. El Amouri, G. Jaouen and J. Vaissermann, Organometallics, 1992, 11, 976; 2952.
- 7 W. S. Sheldrick and A. Gleichmann, J. Organomet. Chem., 1994, 470, 183.
- 8 M. Wenzel, P. Asindraza and G. Schachschneider, J. Labelled Compd. Radiopharm., 1983, 20, 1061; W. H. Soine, C. E. Guyer and F. F. Knapp, jun., J. Med. Chem., 1984, 27, 803.
- 9 P. J. Fagan, M. D. Ward and J. C. Calabrese, J. Am. Chem. Soc., 1989, 11, 1698.
- 10 J. C. Sheehan and G. P. Hess, J. Am. Chem. Soc., 1967, 33, 864; D. F. DeTar, R. Silverstein and F. F. Rogers, jun., J. Am. Chem. Soc., 1966, 88, 1024.
- 11 D. E. Nitecki and J. W. Westley, J. Org. Chem., 1967, 33, 864
- N. Walker and D. Stuart, Acta Crystallogr., Sect. A, 1983, 39, 158.
 G. M. Sheldrick, (a) SHELXS 86, A Program for Structure Determination, Göttingen, 1986; (b) SHELXL 93, A Program for Structure Refinement, Göttingen, 1993.
- 14 S. A. Lomenzo, S. P. Nolan and M. L. Trudell, Organometallics, 1994, 13, 676.
- 15 A. M. McNair, J. L. Schrenk and K. R. Mann, *Inorg. Chem.*, 1984, 23, 2633; J. L. Schrenk, A. M. McNair, F. B. McCormik and K. R. Mann, *Inorg. Chem.*, 1986, 25, 3501.
- 16 R. S. Koefod and K. R. Mann, J. Am. Chem. Soc., 1990, 112, 7287.

Received 29th November 1994; Paper 4/07275H